BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32950428)

  • 1. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812).
    Maggiore RJ; Zahrieh D; McMurray RP; Feliciano JL; Samson P; Mohindra P; Chen H; Wong ML; Lafky JM; Jatoi A; Le-Rademacher JG
    J Geriatr Oncol; 2021 May; 12(4):563-571. PubMed ID: 32950428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
    Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
    Verma V; Moreno AC; Haque W; Fang P; Lin SH
    J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
    [No Abstract]   [Full Text] [Related]  

  • 4. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
    Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
    Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
    Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
    Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
    Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
    Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
    Verschueren MV; Dijs T; Gulikers JL; Veelen AV; Croes S; Hendriks LE; Smit AA; Bloem LT; Egberts AC; van de Garde EM; Peters BJ
    Immunotherapy; 2023 Aug; 15(11):839-851. PubMed ID: 37291888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
    Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
    Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.
    Moreno AC; Haque W; Verma V; Fang P; Lin SH
    Ann Surg Oncol; 2018 May; 25(5):1245-1253. PubMed ID: 29484562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.
    Zhu ZF; Ma HL; Fan M; Bao Y; Zhuang TT; Chen M; Jiang GL; Fu XL
    Technol Cancer Res Treat; 2014 Jun; 13(3):269-75. PubMed ID: 24066952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
    Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
    JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.
    Walraven I; Damhuis RA; Ten Berge MG; Rosskamp M; van Eycken L; de Ruysscher D; Belderbos JSA
    Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):e177-e185. PubMed ID: 28780009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
    Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
    Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
    Garassino MC; Mazieres J; Reck M; Chouaid C; Bischoff H; Reinmuth N; Cove-Smith L; Mansy T; Cortinovis D; Migliorino MR; Delmonte A; Sánchez JG; Chara Velarde LE; Bernabe R; Paz-Ares L; Perez ID; Trunova N; Foroutanpour K; Faivre-Finn C
    J Thorac Oncol; 2022 Dec; 17(12):1415-1427. PubMed ID: 35961520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial.
    Qiu B; Wang D; Li Q; Wu Y; Guo S; Jiang X; Fang J; Guo J; Liu F; Chu C; Wang B; Chen L; Zhang J; Liu Y; Hu Y; Liu H
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):917-925. PubMed ID: 34229051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.
    Sakin A; Sahin S; Atci MM; Sakin A; Yasar N; Geredeli C; Aksaray F; Cihan S
    Pulmonology; 2021; 27(1):26-34. PubMed ID: 31839507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
    Katsui K; Ogata T; Watanabe K; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Acta Med Okayama; 2021 Jun; 75(3):269-277. PubMed ID: 34176930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
    Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
    Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
    Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR
    Front Oncol; 2021; 11():744956. PubMed ID: 34650927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.